In 2007 Prof. Mandrioli became the chief of the Multidisciplinary Centre for MND in Modena, Italy. She created and has been coordinating the population-based Registry of ALS in Modena since 2000, and in Emilia Romagna Region (4.4 million inhab.) since 2009. From 2013 to 2017, she was nominated coordinator of the Italian Study Group on MND. Thanks to her interest in genetics and epidemiology, she carried out several population-based studies on ALS and took part in pharmacological clinical trials plus, together with ITALSGEN Consortium, in seminal international multicentric cooperative efforts leading to the isolation of new genes in ALS. She is currently leading three national non-profit clinical trials for finding a cure in ALS (RAP-ALS, co-ALS, FETR-ALS); her work has been funded thanks to the awarding of multiple national competitive grants. She has published in over 150 peer-reviewed scientific journals, highly mentioned by the scientific community.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.